[Characteristics of type 2 inflammation in nocturnal asthma and evaluation of the effectiveness of inhaled corticosteroids combination therapy].

• DOI: 10.3760/cma.j.cn112137-20240530-01229
• Publication Date: 2025-01-14
• Authors: Y Y; Mingshu Xu; Gefeng Xu; Zhi-qiang Gong; Jianwen Huang; Y Chen; Dalin Hu; Yaping Wang; Jianping Liang; Weidong Zhao; L Y Liu; S X Cai; H J Zhao
• Keywords: Combination therapy

Objective: To investigate the characteristics of type 2 inflammation in patients with nocturnal asthma, and analyze improvement asthma symptoms after use inhaled corticosteroids (ICS) combined different long-acting bronchodilators. Methods: Data 231 who first visited Respiratory Critical Care Medical Clinic Nanfang Hospital Southern University from January 2020 to June 2023 had positive bronchodilator tests (BDT), were retrospectively analyzed. These divided into group non-nocturnal based on presence or absence symptoms. According fractional exhaled nitric oxide (FeNO) levels, inflammatory [FeNO≥20 ppb (×10-12)] non-type (FeNO<20 ppb). Patients further ICS+long-actingβ2 agonist (LABA) ICS+LABA+long-acting anticholinergic agent (LAMA) medication regimens. followed-up at 3rd, 6th, 12th months enrollment evaluate patient's control test (ACT) questionnaire, actual status number acute attacks. The clinical characteristics, treatment prognosis groups compared. Results: A total included, including 152 males 79 females, a age[M (Q1, Q3)] 52 (42, 60) years. There 144 cases (62.3%) 87 (37.7%) group. Among 133 completed FeNO testing, which 95 classified 38 eosinophil (EOS) count level both higher than those [(0.45±0.40) ×109/L vs (0.25±0.20)×109/L, (18, 82) 29 (15, 48) ppb, P<0.05]. Baseline ACT score was lower [16 (14, 18) 21 (19, 23) scores, P<0.001]. no significant difference forced expiratory volume one second (FEV1), vital capacity (FVC), peak flow (PEF) two (both P>0.05). During follow-up months, values scores (ΔACT) [5 (3, 7) (1, 3), 7 (4, 9) 3 4) (6, 5) all EOS [0.40 (0.29, 0.80)×109/L 0.20 (0.12, 0.29)×109/L] percentage [5.10% (3.55%, 9.10%) 2.20% (1.65%, 3.85%)] P<0.05). In group, there ΔACT between ICS+LABA ICS+LABA+LAMA Conclusions: have more pronounced are often not well controlled even worse. After year therapy ICS, improvements can be observed. But is symptom among regimens